- Home
- / NexImmune
NexImmune
Stock Price
$0.3
2024-10-28
Market Capitalization
$372.4 K
2024-10-28
NexImmune Summary
Company Summary
- Overview
- NexImmune is a biopharmaceutical company developing immunotherapy products based on the Artificial Immune Modulation nanotechnology platform. The company focuses on products that help cure cancer by directing T cell function to restore natural immunity.
- Type
- Public
- Status
- Active
- Founded
- 2011
- HQ
- Gaithersburg, MD, US | view all locations
- Website
- https://www.neximmune.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Daniel Bednárik, Senior Vice President, Molecular Engineering and Protein Design
Daniel Bednarik Ph, Senior Vice President, Molecular Engineering and Protein Design
Mathias Oelke, Chief Scientific Officer, Senior Vice President - Head of Preclinical Immunotherapy and Platform Development
Operating MetricsView all
Discovery Phase Products
1
Feb, 2021
Preclinical Phase Products
3
Feb, 2021
Phase I Trials Products
2
Feb, 2021
NexImmune Financials
Summary Financials
- Net income (Q2, 2024)
- ($2.3M)
- Cash (Q2, 2024)
- $2.4M
- EBIT (Q2, 2024)
- ($3.5M)